Specialized Medical Company (4019.SR) — Income statement
Revenue, gross profit, operating income, net income, and EPS for Specialized Medical Company — annual and quarterly.
| Metric (SAR Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 1,538↑301.8% | 383↑5.1% | 364↑13.4% | 321↑14.6% | 280 | |
| Cost of Revenue | 1,156↑309.7% | 282↑3.6% | 272↑9.4% | 249↑12.8% | 221 | |
| Gross Profit | 383↑279.7% | 101↑9.4% | 92↑27.1% | 73↑21.6% | 60 | |
| Operating Expenses | ||||||
| R&D Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| General & Administrative Expenses | 14 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 16 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 30↓20.2% | 38↑7.9% | 35↓9.2% | 39↓6.4% | 41 | |
| Other Expenses | 109 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 140↑269.4% | 38↑7.9% | 35↓9.2% | 39↓6.4% | 41 | |
| Total Costs & Expenses | 1,295↑305.0% | 320↑4.1% | 307↑6.9% | 287↑9.7% | 262 | |
| Operating Results | ||||||
| Operating Income | 243↑285.9% | 63↑10.4% | 57↑68.3% | 34↑84.4% | 18 | |
| Depreciation & Amortization | 93↑299.9% | 23↓0.4% | 23↓15.4% | 28↑0.9% | 27 | |
| EBITDA | 416↑380.2% | 87↑4.8% | 83↑29.3% | 64↑32.9% | 48 | |
| EBIT | 323↑409.6% | 63↑6.8% | 59↑63.3% | 36↑75.0% | 21 | |
| Interest & Other Income | ||||||
| Net Interest Income | -46↓284.5% | -12↑7.3% | -13↓62.8% | -8↓57.7% | -5 | |
| Interest Income | 5 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 51↑325.8% | 12↓7.3% | 13↑62.8% | 8↑57.7% | 5 | |
| Non-Operating Income | -80↓19625.8% | -0.41↑82.2% | -2↑6.5% | -2↓2.3% | -2 | |
| Other Income / Expenses | 29↑352.2% | -12↓8.8% | -11↓93.7% | -5↓108.0% | -3 | |
| Income Before Tax | 273↑429.1% | 52↑10.7% | 47↑63.4% | 28↑80.5% | 16 | |
| Income Tax Expense | 6↑179.6% | 2↑40.3% | 2↑44.8% | 1↑25.0% | 0.88 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 266↑440.4% | 49↑9.7% | 45↑64.1% | 27↑83.8% | 15 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 266↑440.4% | 49↑9.7% | 45↑64.1% | 27↑83.8% | 15 | |
| Bottom-Line Net Income | 266↑440.4% | 49↑9.7% | 45↑64.1% | 27↑83.8% | 15 | |
| EPS (Basic) | 1.06↑430.0% | 0.20↑11.1% | 0.18↑63.6% | 0.11↑84.6% | 0.06 | |
| EPS (Diluted) | 1.06↑430.0% | 0.20↑11.1% | 0.18↑63.6% | 0.11↑84.6% | 0.06 | |
| Weighted Average Shares | 250↑0.0% | 250↑0.0% | 250↑0.0% | 250↑0.0% | 250 | |
| Weighted Average Diluted Shares | 250↑0.0% | 250↑0.0% | 250↑0.0% | 250↑0.0% | 250 | |
* All figures in Millions of SAR, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.